Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 1, 2006, Pages 37-43

  Droste, Jacqueline A H ^a   Kearney, Brian P ^b   Hekster, Yechiel A ^a   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GILEAD SCIENCES   (United States)

Author keywords

Efavirenz; Interaction; Nevirapine; Tenofovir disoproxil fumarate

Indexed keywords

EFAVIRENZ; NEVIRAPINE; TENOFOVIR DISOPROXIL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; LIVER TOXICITY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; REFERENCE VALUE; STATISTICAL ANALYSIS; VALIDATION PROCESS;

ADENINE; ADMINISTRATION, ORAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; OXAZINES; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 28944453305     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000191997.70034.80     Document Type: Article

References (16)

1. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251-265.
2. Anonymous. Gilead Sciences. Available at http://www.gilead.com/pdf/ viread_pi.pdf. Accessed October 5, 2005.
3. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001;45:2733-2739.
4. Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy) propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother. 1998;42:2380-2384.
5. Kearney BP, Flaherty F, Wolf J, et al. Lack of clinically relevant drug-drug interactions between tenofovir DF and efavirenz, indinavir, lamivudine and lopinavir/ritonavir in healthy subjects. Paper presented at: 8th European Conference on Clinical Aspects and Treatment of HIV Infection; October 28-31, 2001; Athens.
6. Hugen PW, Burger DM, Aarnoutse RE, et al. Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance. Ther Drug Monit. 2002;24:579-587.
7. Droste JAH, Verweij-van Wissen CPWGM, Kearney BP, et al. M. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2005;49:680-684.
8. Hollanders RMW, van Ewijk-Beneken Kolmer EWJ, Burger DM, et al. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2000;744:65-71.
9. Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther. 2002;71:57-67.
10. Aarnoutse RE, Verweij-van Wissen CPWGM, van Ewijk-Beneken Kolmer EWJ, et al. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob Agents Chemother. 2002;46:884-886.
11. Droste JA, Aarnoutse RE, Koopmans PP, et al. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003;32:287-291.
12. Holland DT, Difrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS Clinical Trials Group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824-831.
13. Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34(Suppl 1):S21-S33.
14. Veldkamp AI, van Heeswijk RP, Mulder JW, et al. Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine. Ther Drug Monit. 2001;23:606-611.
15. Stocrin summary of product characteristics. Hertfordshire, UK: Merck Sharp & Dohme, Ltd.; 2002.
16. Porte CJL, la Burger DM, Gyssens I, et al. Gender differences in nevirapine pharmacokinetics, fact or fiction? Paper presented at: 4th International Workshop on Clinical Pharmacology of HIV Therapy; March 27-29, 2003; Cannes, France. Abstract 10: P 3.1.